wave left wave right
Image of lung cancer detection technology

Early lung cancer detection using
a standard blood test

75% of lung cancer cases are diagnosed after the disease has progressed1

That’s why EarlyCDT® Lung was developed to find cancer earlier, when it is more treatable.

Lung cancer screening & lung nodule risk assessment with a standard blood draw

For those at high risk of lung cancer:

Aid in the early detection of lung cancer in high‑risk individuals

For those with indeterminate pulmonary nodules:

Provide an effective assessment of lung cancer risk in indeterminate pulmonary nodules (IPNs)

Download EarlyCDT® Lung instructions for use:

Flag of Portugal Portugal
Flag of Romania Romania
Flag of Spain Spain
Flag of the UK United Kingdom

Proprietary autoantibody technology to detect early signs of cancer

The EarlyCDT® Lung test detects the presence of autoantibodies generated by the body’s immune system, a natural defense against cancer cells. This aids in the early detection of lung cancer in high-risk patients.

Female Doctor

Extensively validated in the real world

A randomised controlled trial of 12,000 people in Scotland at high risk of developing lung cancer showed that after two years of follow-up, participants in the EarlyCDT® Lung intervention group saw a significant reduction (37%) in late-stage presentation compared to the control group subject to standard clinical practice.2

Male Doctor

These landmark findings are likely to have globally significant implications for the early detection of lung cancer. A simple blood test, followed by CT scans, is able to increase the number of patients diagnosed at an earlier stage of the disease, when surgery is still possible and prospects for survival much higher.

Professor Frank Sullivan

Professor of Primary Care Medicine at the University of St. Andrews and Chief Investigator for the ECLS trial

Distributors and suppliers

Israel

Best Medical Opinion
Yefe Nof St 1
Givatayim, Israel

Romania

Diamedix Diagnostica
15A Fabrica de Glucoza St.
A4 Building
Bucharest, 2nd District 020331
Romania

Singapore

Weavegen Pte. Ltd
1 Coleman Street
#10-06 The Adelphi
Singapore, 179803

Spain and Portugal

Sabartech S.L.
Parque Científico
Universidad de Valencia,
C/Catedrático Agustín
Escardino, 9, 46980
Paterna, Valencia
Spain

United Kingdom

Cambridge Clinical
Laboratories Limited
Park House, Winship Road
Milton, Cambridge,
Cambridgeshire CB24 6BO
United Kingdom

wave right

Contact

Freenome Ltd (Manufacturer)

MediCity, D6 Thane Road
Nottingham, NG90 6BH
United Kingdom

+44 (0) 115 784 0501

EarlyCDT@freenome.com

qtec EuRep GmbH
(Authorised Representative)

Curtiusstrasse 27
23568 Lübeck
Germany

+49 (4) 51 80 85 03 71

PRRC@qtec-group.com

Back to Top

References

  1. Blandin Knight S, Crosbie PA, Balata H, Chudziak J, Hussell T, Dive C. Progress and prospects of early detection in lung cancer. Open Biol. 2017 Sep;7(9):170070. doi: 10.1098/rsob.170070. PMI 28878044; PMCI PMC5627048.
  2. Sullivan et al. Earlier diagnosis of lung cancer in a randomised trial of an autoantibody blood test followed by imaging. ERJ. 2020, 57(1).